| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Loss from continuing operations | -77,646,737 | -1,978,895 | -2,285,416 | -2,283,413 |
| Loss from discontinued operations | -5,106 | -91,567 | -157,457 | -811,277 |
| Net (loss) | -77,651,843 | -2,070,462 | -2,442,873 | -3,094,690 |
| Net (loss) per common share, basic and diluted (in dollars per share) | -107.25 | -0.23 | -0.34 | -0.48 |
| Us-gaap_weightedaveragenumberofdilutedsharesoutstanding | 723,998 | 9,108,984 | 7,152,221 | 6,396,221 |
| Weighted average shares used in computation basic and diluted (in shares) | 723,998 | 9,108,984 | 7,152,221 | 6,396,221 |
Predictive Oncology Inc. (POAI)
Predictive Oncology Inc. (POAI)